AI Article Synopsis
- COVID-19 cholangiopathy has emerged as a complication in some patients who recovered from severe COVID-19, particularly those who required intensive care and advanced treatments.
- Patients with this condition experience significant liver injury, and a specific type, known as "COVID-19 cast-forming cholangiopathy," is characterized by biliary obstruction.
- There is currently a lack of standard protocols for diagnosing and managing COVID-19 cholangiopathy, with outcomes varying widely among patients, including possibilities of recovery or severe consequences like liver transplant or death.
Article Abstract
The complete impact of COVID-19 infection continues to develop since the onset of the COVID-19 pandemic. COVID-19 cholangiopathy has been recently described in a subset of patients who recovered from severe COVID-19 infection. The most common phenotype of patients suffering from COVID-19 cholangiopathy had severe infection requiring a stay in the intensive care unit, mechanical ventilation and vasopressor medications. Patients with COVID-cholangiopathy present with severe and prolonged cholestatic liver injury. In cases where biliary cast formation is identified, we defined the entity as "COVID-19 cast-forming cholangiopathy". This subset of COVID-19 cholangiopathy is not well understood and there are no standardized diagnosis or management to this date. The reported clinical outcomes are variable, from resolution of symptoms and liver test abnormalities to liver transplant and death. In this commentary, we discuss the proposed pathophysiology, diagnosis, management, and prognosis of this disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066716 | PMC |
| http://dx.doi.org/10.2147/HMER.S384176 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!